The authors observed that in a subgroup of HER2-positive breast cancer patients who developed trastuzumab resistance (three out of five patients), PRKACA expression was highly increased in the breast cancer sample obtained after the onset of trastuzumab resistance compared to the pre-treatment sample. This evidence concerns the gene ERBB2 and breast carcinoma.